UNSPSC 51391607: Propylhexedrine

This classification denotes an alpha-adrenergic agonist with the molecular formula C10H21N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LQU92IU8LL, chemically known as propylhexedrine, dl- but generally known as propylhexedrine, which bears US NIH Compound Identifier 7558. European Medicines Agency schedules Propylhexedrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10121MIG. The term PROPYLHEXEDRINE is an International Non-Proprietary Name.

UNSPSC 51391607 Propylhexedrine, a Commodity code, appears in recent state and local solicitations for pharmaceutical products and drug-related public health supplies, though the opportunities tagged under it diverge significantly from the code's nominal scope. Seminole County, Florida issued IFB 60459723LAS to procure naloxone and drug deactivation systems annually—1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries—while the Texas Health and Human Services Commission released an RFI to explore direct-to-manufacturer prescription fulfillment models outside traditional pharmacy benefit manager and group purchasing organization channels. The actual work being solicited centers on pharmaceutical procurement for public health intervention and emergency response, not propylhexedrine specifically. Issuing bodies include county-level health authorities and state health agencies; the Seminole County opportunity reflects the kind of local government health department purchasing that drives activity in this space, though the narrow recent sample limits any characterization of repeat buyers.

The geographic spread evident in recent opportunities is limited to Florida and Texas. Seminole County's IFB closed with a response deadline of July 26, 2023, calling for bids on a fixed-fee basis with a two-year initial term and one-year renewal option, while the Texas HHS Commission's RFI (posted April 3, 2026, with the same response deadline) sought vendor capabilities for direct prescription contracting—a preliminary information-gathering mechanism rather than a formal competitive award. The code shows minimal recent activity aligned with its narrow pharmaceutical scope; the tagged opportunities reflect pharmaceutical procurement broadly rather than propylhexedrine as a product line. Business development interest in this code should weight the significant mismatch between the code label and what state and local governments are actually buying under it against the limited visibility into repeat or pipeline activity.